Genetic susceptibility to acute graft versus host disease in pediatric patients undergoing HSCT.


Journal

Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459

Informations de publication

Date de publication:
11 2021
Historique:
received: 08 03 2021
accepted: 21 06 2021
revised: 28 05 2021
pubmed: 4 7 2021
medline: 11 3 2022
entrez: 3 7 2021
Statut: ppublish

Résumé

The most frequent complication of allogeneic hematopoietic stem cell transplantation is acute Graft versus Host Disease (aGVHD). Proliferation and differentiation of donor T cells initiate inflammatory response affecting the skin, liver, and gastrointestinal tract. Besides recipient-donor HLA disparities, disease type, and the conditioning regimen, variability in the non-HLA genotype have an impact on aGVHD onset, and genetic variability of key cytokines and chemokines was associated with increased risk of aGVHD. To get further insight into the recipient genetic component of aGVHD grades 2-4 in pediatric patients, we performed an exome-wide association study in a discovery cohort (n = 87). Nine loci sustained correction for multiple testing and were analyzed in a validation group (n = 168). Significant associations were replicated for ERC1 rs1046473, PLEK rs3816281, NOP9 rs2332320 and SPRED1 rs11634702 variants through the interaction with non-genetic factors. The ERC1 variant was significant among patients that received the transplant from HLA-matched related individuals (p = 0.03), bone marrow stem cells recipients (p = 0.007), and serotherapy-negative patients (p = 0.004). NOP9, PLEK, and SPRED1 effects were modulated by stem cell source, and serotherapy (p < 0.05). Furthermore, ERC1 and PLEK SNPs correlated with aGVHD 3-4 independently of non-genetic covariates (p = 0.02 and p = 0.003). This study provides additional insight into the genetic component of moderate to severe aGVHD.

Identifiants

pubmed: 34215854
doi: 10.1038/s41409-021-01386-8
pii: 10.1038/s41409-021-01386-8
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2697-2704

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Adom D, Rowan C, Adeniyan T, Yang J, Paczesny S. Biomarkers for allogeneic HCT outcomes. Front Immunol. 2020;11:673.
Shaw PJ, Kan F, Woo Ahn K, Spellman SR, Aljurf M, Ayas M, et al. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood. 2010;116:4007–15.
pubmed: 20671124 pmcid: 2981549 doi: 10.1182/blood-2010-01-261958
Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR Jr., Ringdén O, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol. 2004;22:4872–80.
pubmed: 15520055 doi: 10.1200/JCO.2004.02.189
Alsultan A, Giller RH, Gao D, Bathurst J, Hild E, Gore L, et al. GVHD after unrelated cord blood transplant in children: characteristics, severity, risk factors and influence on outcome. Bone Marrow Transplant. 2011;46:668–75.
pubmed: 20676147 doi: 10.1038/bmt.2010.174
Zeiser R, Blazar BR. Acute graft-versus-host disease—biologic process, prevention, and therapy. N Engl J Med. 2017;377:2167–79.
pubmed: 29171820 pmcid: 6034180 doi: 10.1056/NEJMra1609337
Martínez-Laperche C, Buces E, Aguilera-Morillo MC, Picornell A, González-Rivera M, Lillo R, et al. A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. Blood Adv. 2018;2:1719–37.
pubmed: 30030270 pmcid: 6058238 doi: 10.1182/bloodadvances.2017011502
Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550–61.
pubmed: 19282026 pmcid: 2735047 doi: 10.1016/S0140-6736(09)60237-3
Dzierzak-Mietla M, Markiewicz M, Siekiera U, Mizia S, Koclega A, Zielinska P, et al. Occurrence and impact of minor histocompatibility antigens’ disparities on outcomes of hematopoietic stem cell transplantation from HLA-matched sibling donors. Bone Marrow Res. 2012;2012:257086.
pubmed: 23193478 pmcid: 3502767 doi: 10.1155/2012/257086
Martin PJ, Levine DM, Storer BE, Warren EH, Zheng X, Nelson SC, et al. Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. Blood. 2017;129:791–8.
pubmed: 27872059 pmcid: 5301826 doi: 10.1182/blood-2016-09-737700
Kim DDH, Yun J, Won H-H, Cheng L, Su J, Xu W, et al. Multiple single-nucleotide polymorphism-based risk model for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease. Transplantation. 2012;94:1250–7.
pubmed: 23169244 doi: 10.1097/TP.0b013e3182708e7c
Ansari M, Curtis PH, Uppugunduri CRS, Rezgui MA, Nava T, Mlakar V, et al. GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. Oncotarget. 2017;8:90852–67.
pubmed: 29207608 pmcid: 5710889 doi: 10.18632/oncotarget.20310
Ansari M, Petrykey K, Rezgui MA, Del Vecchio V, Cortyl J, Ralph RO, et al. Genetic susceptibility to hepatic sinusoidal obstruction syndrome in pediatric patients undergoing hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2020;26:920–7.
pubmed: 31790828 doi: 10.1016/j.bbmt.2019.11.026
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–8.
pubmed: 7581076
Holtan SG, Khera N, Levine JE, Chai X, Storer B, Liu HD, et al. Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood. 2016;128:2350–8.
pubmed: 27625357 pmcid: 5106113 doi: 10.1182/blood-2015-09-669846
Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for human genetic variation. Nature. 2015;526:68–74.
pubmed: 26432245 doi: 10.1038/nature15393
Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;Chapter 7:Unit7 20.
Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073–81.
pubmed: 19561590 doi: 10.1038/nprot.2009.86
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559–75.
pubmed: 17701901 pmcid: 1950838 doi: 10.1086/519795
Benjamini YH, Controlling Y. the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B: Methodol. 1995;57:289–300.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
doi: 10.1038/bmt.2012.244 pubmed: 23208313
Labuda D, Krajinovic M, Richer C, Skoll A, Sinnett H, Yotova V, et al. Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay. Anal Biochem. 1999;275:84–92.
pubmed: 10542112 doi: 10.1006/abio.1999.4293
Huezo-Diaz P, Uppugunduri CR, Tyagi AK, Krajinovic M, Ansari M. Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children. Curr Drug Metab. 2014;15:251–64.
pubmed: 24524663 doi: 10.2174/1389200215666140202214012
Zhu Q, Yan L, Liu Q, Zhang C, Wei L, Hu Q, et al. Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. Blood. 2018;131:2490–9.
pubmed: 29610366 pmcid: 5981168 doi: 10.1182/blood-2017-11-817973
Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023-.
pubmed: 29158945 pmcid: 5661633 doi: 10.1038/sigtrans.2017.23
Magenau J, Runaas L, Reddy P. Advances in understanding the pathogenesis of graft-versus-host disease. Br J Haematol. 2016;173:190–205.
pubmed: 27019012 doi: 10.1111/bjh.13959
Jeanette LDS, Bottero V, Young DB, Shevchenko A, Mercurio F, Verma IM. Activation of transcription factor NF-κB requires ELKS, an IκB kinase regulatory subunit. Science. 2004;304:1963–7.
doi: 10.1126/science.1098387
Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–8.
pubmed: 19847258 pmcid: 2906700 doi: 10.1038/nature08467
Kuba A, Raida L, Mrazek F, Schneiderova P, Kriegova E, Langova K, et al. NFKB1 gene single-nucleotide polymorphisms: implications for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2020;99:609–18.
pubmed: 32002656 doi: 10.1007/s00277-020-03935-5
Alpay M, Backman LR, Cheng X, Dukel M, Kim WJ, Ai L, et al. Oxidative stress shapes breast cancer phenotype through chronic activation of ATM-dependent signaling. Breast Cancer Res Treatment. 2015;151:75–87.
doi: 10.1007/s10549-015-3368-5
Liu CJ, Fu X, Xia M, Zhang Q, Gu Z, Guo AY. miRNASNP-v3: a comprehensive database for SNPs and disease-related variations in miRNAs and miRNA targets. Nucleic Acids Res. 2020;49:D1276–81.
Gong J, Tong Y, Zhang HM, Wang K, Hu T, Shan G, et al. Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat. 2012;33:254–63.
pubmed: 22045659 doi: 10.1002/humu.21641
Medrano LM, Pascual V, Bodas A, López-Palacios N, Salazar I, Espino-Paisán L, et al. Expression patterns common and unique to ulcerative colitis and celiac disease. Ann Hum Genet. 2019;83:86–94.
pubmed: 30402962 doi: 10.1111/ahg.12293
Hoppmann N, Graetz C, Paterka M, Poisa-Beiro L, Larochelle C, Hasan M, et al. New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis. Brain. 2015;138(Pt 4):902–17.
pubmed: 25665584 doi: 10.1093/brain/awu408
Lundmark A, Davanian H, Båge T, Johannsen G, Koro C, Lundeberg J, et al. Transcriptome analysis reveals mucin 4 to be highly associated with periodontitis and identifies pleckstrin as a link to systemic diseases. Sci Rep. 2015;5:18475.
pubmed: 26686060 pmcid: 4685297 doi: 10.1038/srep18475
Ding Y, Kantarci A, Badwey JA, Hasturk H, Malabanan A, Van Dyke TE. Phosphorylation of Pleckstrin increases proinflammatory cytokine secretion by mononuclear phagocytes in diabetes mellitus. J Immunol. 2007;179:647–54.
pubmed: 17579087 doi: 10.4049/jimmunol.179.1.647
Hasturk H, Kantarci A, Van Dyke TE. Oral inflammatory diseases and systemic inflammation: role of the macrophage. Front Immunol. 2012;3:118.
pubmed: 22623923 pmcid: 3353263 doi: 10.3389/fimmu.2012.00118
Battle A, Brown CD, Engelhardt BE, Montgomery SB. Genetic effects on gene expression across human tissues. Nature. 2017;550:204–13.
pubmed: 29022597 doi: 10.1038/nature24277
Pasmant E, Gilbert-Dussardier B, Petit A, de Laval B, Luscan A, Gruber A, et al. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia. Oncogene. 2015;34:631–8.
pubmed: 24469042 doi: 10.1038/onc.2013.587
Olsson L, Castor A, Behrendtz M, Biloglav A, Forestier E, Paulsson K, et al. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. Leukemia. 2014;28:302–10.
pubmed: 23823658 doi: 10.1038/leu.2013.206
Jansen F, Yang X, Hoelscher M, Cattelan A, Schmitz T, Proebsting S, et al. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation. 2013;128:2026–38.
pubmed: 24014835 doi: 10.1161/CIRCULATIONAHA.113.001720
Biedermann BC. Vascular endothelium and graft-versus-host disease. Best Practice Res Clin Haematol. 2008;21:129–38.
doi: 10.1016/j.beha.2008.02.003
Tichelli A, Gratwohl A. Vascular endothelium as ‘novel’ target of graft-versus-host disease. Best Practice Res Clin Haematol. 2008;21:139–48.
doi: 10.1016/j.beha.2008.02.002
Cao X-N, Kong Y, Song Y, Shi M-M, Zhao H-Y, Wen Q, et al. Impairment of bone marrow endothelial progenitor cells in acute graft-versus-host disease patients after allotransplant. Br J Haematol. 2018;182:870–86.
pubmed: 29984829 doi: 10.1111/bjh.15456
Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol. 2008;8:478–86.
pubmed: 18483499 pmcid: 2855166 doi: 10.1038/nri2327
Leveson-Gower DB, Sega EI, Kalesnikoff J, Florek M, Pan Y, Pierini A, et al. Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells. Blood. 2013;122:3659–65.
pubmed: 24030387 pmcid: 3837515 doi: 10.1182/blood-2013-08-519157
Ishizaki T, Tamiya T, Taniguchi K, Morita R, Kato R, Okamoto F, et al. miR126 positively regulates mast cell proliferation and cytokine production through suppressing Spred1. Genes Cells. 2011;16:803–14.
pubmed: 21668589 doi: 10.1111/j.1365-2443.2011.01529.x
Suzuki M, Morita R, Hirata Y, Shichita T, Yoshimura A. Spred1, a suppressor of the Ras-ERK pathway, negatively regulates expansion and function of group 2 innate lymphoid cells. J Immunol. 2015;195:1273–81.
pubmed: 26116510 doi: 10.4049/jimmunol.1500531
Munneke JM, Björklund AT, Mjösberg JM, Garming-Legert K, Bernink JH, Blom B, et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood. 2014;124:812–21.
pubmed: 24855210 doi: 10.1182/blood-2013-11-536888
Thomson E, Rappsilber J, Tollervey D. Nop9 is an RNA binding protein present in pre-40S ribosomes and required for 18S rRNA synthesis in yeast. RNA. 2007;13(12):2165–74.
pubmed: 17956976 pmcid: 2080597 doi: 10.1261/rna.747607
Zhang J, Teramoto T, Qiu C, Wine RN, Gonzalez LE, Baserga SJ, et al. Nop9 recognizes structured and single-stranded RNA elements of preribosomal RNA. RNA. 2020;26(8):1049–59.
pubmed: 32371454 pmcid: 7373996 doi: 10.1261/rna.075416.120
Nudel R, Simpson NH, Baird G, O’Hare A, Conti-Ramsden G, Bolton PF, et al. Genome-wide association analyses of child genotype effects and parent-of-origin effects in specific language impairment. Genes Brain Behav. 2014;13(4):418–29.
pubmed: 24571439 pmcid: 4114547 doi: 10.1111/gbb.12127
Turpeinen H, Ojala PJ, Ojala K, Miettinen M, Volin L, Partanen J. Minor histocompatibility antigens as determinants for graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Int J Immunogenet. 2013;40(6):495–501.
pubmed: 23480177 doi: 10.1111/iji.12051
Akatsuka Y, Warren EH, Gooley TA, Brickner AG, Lin M-T, Hansen JA, et al. Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br J Haematol. 2003;123:671–5.
pubmed: 14616971 doi: 10.1046/j.1365-2141.2003.04676.x
Sharma SB, Lin CC, Farrugia MK, McLaughlin SL, Ellis EJ, Brundage KM, et al. MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1. Mol Cell Biol. 2014;34:4143–64.
pubmed: 25202123 pmcid: 4248710 doi: 10.1128/MCB.00480-14

Auteurs

Marc Ansari (M)

Cansearch research platform for paediatric oncology and haematology, Department of Paediatrics, Gynaecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Department of Women, Child and Adolescent, Onco-Hematology Unit, Geneva University Hospital, Geneva, Switzerland.

Kateryna Petrykey (K)

Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada.
Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.

Mohamed Aziz Rezgui (MA)

Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada.

Veronica Del Vecchio (V)

Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada.
Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.

Jacques Cortyl (J)

Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada.

Milad Ameur (M)

Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada.
Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.

Tiago Nava (T)

Cansearch research platform for paediatric oncology and haematology, Department of Paediatrics, Gynaecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Department of Women, Child and Adolescent, Onco-Hematology Unit, Geneva University Hospital, Geneva, Switzerland.

Patrick Beaulieu (P)

Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada.

Pascal St-Onge (P)

Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada.

Simona Jurkovic Mlakar (SJ)

Cansearch research platform for paediatric oncology and haematology, Department of Paediatrics, Gynaecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Department of Women, Child and Adolescent, Onco-Hematology Unit, Geneva University Hospital, Geneva, Switzerland.

Chakradhara Rao S Uppugunduri (CRS)

Cansearch research platform for paediatric oncology and haematology, Department of Paediatrics, Gynaecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Department of Women, Child and Adolescent, Onco-Hematology Unit, Geneva University Hospital, Geneva, Switzerland.

Yves Théoret (Y)

Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada.
Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.
Clinical Pharmacology Unit, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada.

Imke H Bartelink (IH)

Pediatric Blood and Marrow Transplantation Program, University Medical Center Utrecht, Utrecht, The Netherlands.
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Pharmacology and Pharmacy, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Jaap-Jan Boelens (JJ)

Pediatric Blood and Marrow Transplantation Program, University Medical Center Utrecht, Utrecht, The Netherlands.
Stem cell transplantation and cellular therapy program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Robbert G M Bredius (RGM)

Department of Pediatrics, Division of Immunology, Infectious Diseases and SCT, Leiden University Medical Center, Leiden, The Netherlands.

Jean-Hugues Dalle (JH)

Pediatric Hematology Department, Robert Debré Hospital, Assistance Publique, Hôpitaux de Paris and Paris-Diderot University, Paris, France.

Victor Lewis (V)

Department of Oncology, Alberta Children's Hospital, Calgary, AB, Canada.

Bill S Kangarloo (BS)

Department of Oncology, Alberta Children's Hospital, Calgary, AB, Canada.

Selim Corbacioglu (S)

Department of Hematology, Oncology, and Stem Cell Transplantation University Children's Hospital Regensburg, Regensburg, Germany.

Daniel Sinnett (D)

Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada.
Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.

Henrique Bittencourt (H)

Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada.
Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.

Maja Krajinovic (M)

Charles-Bruneau Cancer Center, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada. maja.krajinovic@umontreal.ca.
Department of Pharmacology and Physiology, Faculty of Medicine, University of Montreal, Montreal, QC, Canada. maja.krajinovic@umontreal.ca.
Clinical Pharmacology Unit, Sainte-Justine University Health Center (SJUHC), Montreal, QC, Canada. maja.krajinovic@umontreal.ca.
Department of Pediatrics, Faculty of Medicine, University of Montreal, Montreal, QC, Canada. maja.krajinovic@umontreal.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH